{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069819","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.031870+00:00","generated_at":"2026-05-21T17:33:05.837376+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Coya Therapeutics Q1 net loss $7.3M; pipeline milestones for COYA 302 detailed","bullets":["Net loss of $7.3M in Q1 2025 vs $5.1M in Q1 2024; R&D expense rose to $5.2M from $3.1M.","Cash and cash equivalents $35.5M as of March 31, 2025.","Positive interim results from investigator-initiated trial of LD IL-2 + CTLA4-Ig in Frontotemporal Dementia.","Expects IND submission for COYA 302 in ALS in Q2 2025; $8.4M milestone from DRL due upon first dosing.","Plans to file IND for COYA 302 in FTD by end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069819","json":"https://secwatch.observer/filing/0000950170-25-069819.json","markdown":"https://secwatch.observer/filing/0000950170-25-069819.md","text":"https://secwatch.observer/filing/0000950170-25-069819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000095017025069819/0000950170-25-069819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000095017025069819/coya-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T17:33:05.837376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}